Frontiers | Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
JCM | Free Full-Text | Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies - ScienceDirect
TAS 102 mechanism of action compared to 5-FU | Download Scientific Diagram
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer - ScienceDirect
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with Y resin microspheres for chemo-refractory colorectal liver metastases.
TAS-102 for Refractory mCRC
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with 90Y resin microspheres for chemo-refractory colorectal liver metastases | BMC Cancer | Full Text
Chemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
Result of the PII trial of TAS-102 in third/fourth line colorectal... | Download Scientific Diagram
Initial experience of TAS-102 chemotherapy in Australian patients with chemo-refractory metastatic colorectal cancer
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Chemo In a Bottle: Oral Chemotherapy for Colorectal Cancer
TAS-102 treatment induces trifluridine incorporation into DNAs and cell... | Download Scientific Diagram
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts | Anticancer Research
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer - ScienceDirect
HEALTHCARE PROFESSIONALS
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS- 102)
Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with Y resin microspheres for chemo-refractory colorectal liver metastases.
Frontiers | A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Chemorefractory Metastatic Colorectal Cancer: TAS ppt download
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
Comparison of Phase III trials evaluating TAS-102 and regorafenib | Download Table
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research
Efectividad y seguridad de regorafenib y trifluridina/tipiracilo en cáncer colorrectal metastático - ILAPHAR | Revista de la OFIL
Efectividad y seguridad de regorafenib y trifluridina/tipiracilo en cáncer colorrectal metastático - ILAPHAR | Revista de la OFIL
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology
